Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05122936

Observation on Obesity Undergoing XOWI

Obesity becomes a worldwide chronic health problem, including China. Meta-analyses showed in recent years anti-obesity effects of Chinese herbal therapy (CHT) in overweight and obese patients. However, there are still few observational studies on its effect in patients undergoing CHT more than 6 months, or on its safety. This is a mono-centric, prospective study conducted at Shanghai Municipal Hospital of Traditional Chinese Medicine. Patients with body mass index ≥ 28 Kg/m2 and chartered by heat-dampness is consecutively recruited. All the patients will undergo an integrated SRXPY-based Obesity Wellness Intervention (lifestyle invention + XRXP granule). Patients will be instructed by Traditional Chinese Medicine(TCM) practitioner and nutritionist. They will be investigated every 3 months, until 2 years after enrollment. The study will test anti-obesity effect and safety of the integrated obesity wellness intervention, and test changes of appetite, health-related quality of life, bio markers as well.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Shanghai Municipal Hospital of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, 200071, China

About this study

Obesity is a worldwide problem to public health, with a prevalence rate of 12.4% according to recent studies. It is associated with a series of chronic non-communicable diseases, including type 2 diabetes, cardiovascular diseases, non-alcoholic fatty liver, polycystic ovary syndrome, cancer, and so on. Many publications reported Chinese herbal therapy as an effective anti- obesity management. However, there are still few observational studies on its effect in patients undergoing Chinese herbal therapy more than 6 months, or on its safety.

This is a mono-centric, prospective study conducted at Shanghai Municipal Hospital of Traditional Chinese Medicine. Patients with body mass index ≥ 28 Kg/m2 will be consecutively recruited in out-patient clinic of the department of endocrinology or nutrition. Another important including criteria is that each subject is supposed to be chartered by heat-dampness pattern in TCM. Patients will undergo an integrated SRXPY-based obesity wellness intervention(SOWI). They will report weekly diet, daytime physical activities and sleeping time, by means of WeChat and Electrical bracelet. Meanwhile, TCM practitioner and nutritionist will be involved in helping them.

The integrated obesity wellness intervention is based on lifestyle invention and XRXP granule. XRXP granule is composed of several herbs, such as Huang Qin (Baical Skullcap Root), Zi Cao (Root of Sinkiang Arnebia), Hu Zhang (Rhizoma Polygoni cuspidata), Cang Shu (Atractylodis Rhizoma), He Ye (Lotus Leaf), etc. Some components have been found, which can ameliorate serum concentrations of glucagon-like peptide-1 by stimulating gut taste receptors in db/db mice. Also, XRXP granule showed anti-obesity effects (reduction of body weight, body mass index and waist circumstance) in a 12-week pilot study on obese patients.

In this observational study, patients will be investigated every 3 months, until 2 years after enrollment. We will not only test the effect and safety, but test changes of appetite, health- related quality of life, bio markers as well.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

·age ranged from 16-70 years old body mas index over 28kg/m2

Exclusion criteria

  • secondary cause of obesity such as hypothalamic obesity, cushing syndrome, and hypophysis dysfunction, etc.
  • pregnancy or lactation
  • significant dysfunction of heart, liver, kidney and systemic organs (NYHA Class III or IV; alanine aminotransferase(ALT) and / or aspartate aminotransferase(AST) ≥ 5 times the normal upper limit; glomerular filtration rate< 60(ml/min) or with malignant tumor
  • body weight fluctuated by more than 5 kg in the last 3 months with drug abuse or alcohol addiction
  • with serious mental and neurological disorders
  • blood pressure ≥ 180/110 mmHg, or malignant hypertension
  • organic and systemic diseases intolerant of herb

Treatment and study plan

XRXPY-based Obesity Wellness Intervention(SOWI)

Combination Product

It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.

Primary outcomes

  1. Mean Percent Change in Body Weight

    Time frame: 2021-2027

    Measuring body weight at the required time point

  2. Percentage of Participants who Achieve ≥5% Body Weight Reduction

    Time frame: 2021-2027

    Measuring body weight at the required time point

Secondary outcomes

  1. Percentage of participants who achieve ≥10% body weight reduction

    Time frame: 2021-2027

    Measuring body weight at the required time point

  2. Percentage of participants who achieve ≥15% body weight reduction

    Time frame: 2021-2027

    Measuring body weight at the required time point

  3. Change in waist circumference

    Time frame: 2021-2027

    Measuring waist circumference at the required time point

  4. Change in glycosylated hemoglobin A-1c(Hba1c)

    Time frame: 2021-2027

    Measuring Hba1c at the required time point

  5. Change in fasting blood glucose

    Time frame: 2021-2027

    Measuring fasting blood glucose at the required time point

  6. Change in Three-Factor eating questionnaire(TFEQ-R21)

    Time frame: 2021-2027

    Investigating TFEQ-R21 at the required time point

  7. Change in food craving questionnaire-trait(FCQ-T)

    Time frame: 2021-2027

    Investigating FCQ-T at the required time point

  8. Change in Impact of weight quality of life-lite(IWQOL-Lite)

    Time frame: 2021-2027

    Investigating IWQOL-Lite at the required time point,higher scores indicate better quality of life on the IWQOL-Lite(0-100).

  9. Change in the medical outcomes study item short from health survey-short from(SF-36)

    Time frame: 2021-2027

    Investigating SF-36 at the required time point,higher scores indicate better quality of life on the SF-36(0-100).

  10. Change in cholecystokinin(CCK)

    Time frame: 2021-2027

    Measuring CCK in serum at the required time point

  11. Change in bile acid

    Time frame: 2021-2027

    Measuring bile acid in serum and feces at the required time point

  12. Change in peptide YY(PYY)

    Time frame: 2021-2027

    Measuring PYY in serum at the required time point

  13. Change in ghrelin(GHRL)

    Time frame: 2021-2027

    Measuring GHRL in serum at the required time point

Sponsors and collaborators

Lead sponsor

Feng Tao

Other

Registry information

Official study title

The Observation Study on Obesity Cohort Undergoing XRXPY-based Obesity Wellness Intervention

Important dates

Study start
2021
Primary completion
2026
Study completion
2027
First posted
Nov 17, 2021
Registry last updated
Mar 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.